Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

被引:0
|
作者
Tomohiro Kawaguchi
Yukihiko Sonoda
Ichiyo Shibahara
Ryuta Saito
Masayuki Kanamori
Toshihiro Kumabe
Teiji Tominaga
机构
[1] Tohoku University Graduate School of Medicine,Department of Neurosurgery
[2] Yamagata University School of Medicine,Department of Neurosurgery, Faculty of Medicine
[3] Kitasato University School of Medicine,Department of Neurosurgery
来源
Journal of Neuro-Oncology | 2016年 / 129卷
关键词
Glioma; WHO grade III; IDH; 1p/19q; Surgery; Magnetic resonance imaging;
D O I
暂无
中图分类号
学科分类号
摘要
The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.
引用
收藏
页码:505 / 514
页数:9
相关论文
共 50 条
  • [21] The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas
    Zhao, Kai
    Sun, Guochen
    Wang, Qun
    Xue, Zhe
    Liu, Gang
    Xia, Yirong
    Yao, Anhui
    Zhao, Yue
    You, Na
    Yang, Chenxuan
    Xu, Bainan
    ACADEMIC RADIOLOGY, 2021, 28 (07) : E189 - E198
  • [22] AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS
    Hu, Xin
    Martinez-Ledesma, Emmanuel
    Zheng, Siyuan
    Kim, Hoon
    Barthel, Floris
    Jiang, Tao
    Hess, Kenneth R.
    Verhaak, Roel
    NEURO-ONCOLOGY, 2016, 18 : 213 - 213
  • [23] Characterizing the breakpoint of 1p/19q co-deletion in glioma with long-read sequence technology
    Sugawa, Masahiro
    Kimura, Keisuke
    Sakamoto, Yoshitaka
    Ochi, Yotaro
    Nakamura, Wataru
    Mateos, Raul
    Chiba, Kenichi
    Okada, Ai
    Okuda, Rurika
    Tsujimura, Taro
    Ohka, Fumiharu
    Motomura, Kazuya
    Kato, Motohiro
    Saito, Ryuta
    Ogawa, Seishi
    Shiraishi, Yuichi
    CANCER SCIENCE, 2025, 116 : 1115 - 1115
  • [24] Comparison of FISH and NGS Based 1p/19q Co-Deletion in Gliomas
    Stougaard, M.
    Johnsen, L. O.
    Thomsen, R.
    Holm, K.
    Jakobsen, A. -K.
    Franch, O.
    Knudsen, B. R.
    Riber-Hansen, R.
    Steiniche, T.
    Ulhoi, B. P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (03): : S55 - S55
  • [25] No 1p/19q Co-deletion Identified in Oligodendroglial Component within Glioblastomas
    Piao, Zhe
    Chhabra, Vaninder
    Stiner, Eric
    Goldenberg, Todd
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2015, 74 (06): : 637 - 637
  • [26] Recurrent spinal oligodendroglioma with neurocytic differentiation and 1p/19q co-deletion
    Aizpurua, M.
    King, A. P.
    Laxton, R.
    Doey, L.
    Bodi, I.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2014, 40 : 47 - 47
  • [27] Correlation of IDH mutation, 1p/19q co-deletion and 18FET-PET derived time-to-peak analysis as prognostic markers in glioma
    Suchorska, Bogdana
    Kraus, Theo
    Biczok, Annamaria
    Weller, Michael
    Unterrainer, Marcus
    Schueller, Ulrich
    Schmid-Tannwald, Christine
    Bartenstein, Peter
    Gies, Armin
    Tonn, Joerg
    Albert, Nathalie Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Impact of IDH Mutations, the 1p/19q Co-Deletion and the G-CIMP Status on Alternative Splicing in Diffuse Gliomas
    Zhang, Lu
    Fritah, Sabrina
    Nazarov, Petr V.
    Kaoma, Tony
    Van Dyck, Eric
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (12)
  • [29] Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
    Iwamoto, Fabio M.
    Nicolardi, Linda
    Demopoulos, Alexis
    Barbashina, Violetta
    Salazar, Paulo
    Rosenblum, Marc
    Hormigo, Adilia
    JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (03) : 293 - 298
  • [30] Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
    Fabio M. Iwamoto
    Linda Nicolardi
    Alexis Demopoulos
    Violetta Barbashina
    Paulo Salazar
    Marc Rosenblum
    Adília Hormigo
    Journal of Neuro-Oncology, 2008, 88 : 293 - 298